The Surge In Neurological Illnesses And The Central Nervous System Biomarker Market: Critical Driver Shaping the Central Nervous System Biomarkers Market in 2025

"Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Central Nervous System Biomarkers Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size of central nervous system biomarkers has seen exponential growth in the past few years. Its valuation is expected to rise from $5.58 billion in 2024, to approximately $6.15 billion in 2025, at a compound annual growth rate (CAGR) of 10.2%. Factors contributing to this upward trend during the historical period include heightened awareness about neurological disorders, an increase in instances of central nervous system diseases, surging demand for superior diagnostic and treatment methods, advancements in healthcare infrastructure, and an upturn in the elderly population.

Central Nervous System Biomarkers Market Size Forecast: What's the Projected Valuation by 2029?
The market size of biomarkers for the central nervous system is anticipated to experience substantial growth in the upcoming years, increasing to a value of $9 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 10.0%. This predicted growth during the forecast period is due to factors such as the rising occurrence of neurological disorders, increasing preference for personalized medicine, growth in the elderly population, ongoing emphasis on early diagnosis, and increased interest in non-invasive diagnostic methods. The forecast period is further characterized by emerging technological advancements, strategic partnerships amongst biotech firms, pharmaceutical companies, and other relevant parties, increase in cerebrospinal fluid (csf) and blood-based biomarkers research, as well as the application of artificial intelligence and machine learning algorithms.

View the full report here:
https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

What Are the Drivers Transforming the Central Nervous System Biomarkers Market?
The central nervous system biomarker market is projected to grow due to an increase in neurological diseases. These diseases, also termed as neurological disorders, encompasses a wide array of conditions impacting the brain, spinal cord, and nerves in the body. They are caused due to various factors, such as genetic influences, infections, autoimmune reactions, degeneration, tumors, vascular problems, and injuries. Central nervous system (CNS) biomarkers significantly contribute to the clinical diagnosis of these disorders, evaluation of disease risk or outlook, and determining treatment response. Furthermore, they offer an improved understanding of these disorders and their treatability. For example, as mentioned by the Centers for Disease Control and Prevention, a US government agency, in April 2023, Alzheimer's disease was seen in nearly 6.7 million American citizens aged 65 or older. This figure is predicted to triple up, reaching 14 million by 2060. Additionally, it is observed that the prevalence of the disease doubles every five years after the age of 65. As such, the upsurge in neurological diseases propels the growth of the central nervous system biomarker market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12632&type=smp

What Long-Term Trends Will Define the Future of the Central Nervous System Biomarkers Market?
The trend of getting approvals for innovative drugs has been garnering attention in the central nervous system biomarker market. Large companies in this market are creating fresh drugs and seeking their approval in an attempt to solidify their position. For example, Denovo Biopharma LLC, a US clinical-stage biopharmaceutical organization, made an announcement in January 2022 regarding FDA approval for the company's investigational new drug (IND) application of DB104 (liafensine) for managing treatment-resistant depression (TRD). It is the first TRD global CNS clinical trial guided by biomarkers. Further, the drug can potentially help identify patients likely to respond positively to liafensine, aiding in making more personalized treatment calls. Liafensine is a unique compound which functions by enhancing the level of dopamine and norepinephrine in the brain.

Which Segments in the Central Nervous System Biomarkers Market Offer the Most Profit Potential?
The central nervous system biomarkers market covered in this report is segmented -

1) By Type: Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Types
2) By Disease: Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, Traumatic Brain Injury, Other Diseases
3) By Application: Drug Discovery And Development, Personalized Medicines, Disease Risk Assessment, Diagnostics, Other Applications
4) By End-Users: Diagnostic Labs, Clinics, Hospitals, Research Centers, Other End-Users

Subsegments:
1) By Safety Biomarker: Toxicity Biomarkers, Adverse Event Biomarkers
2) By Efficacy Biomarker: Pharmacodynamic Biomarkers, Response Biomarkers
3) By Validation Biomarker: Predictive Biomarkers, Prognostic Biomarkers
4) By Other Types: Diagnostic Biomarkers, Biomarkers For Disease Progression

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12632&type=smp

Which Firms Dominate the Central Nervous System Biomarkers Market by Market Share and Revenue in 2025?
Major companies operating in the central nervous system biomarkers market include F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Abastar Mdx Inc., Banyan Biomarkers Inc., Avacta Group PLC, Geno Technology Inc., Anavex Life Sciences Corp., Alseres Pharmaceuticals Inc., Aposense Ltd., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Abiant Inc., Avid Radiopharmaceuticals Inc., Acumen Pharmaceuticals Inc., Cassava Sciences Inc., Denali Therapeutics

Which Regions Offer the Highest Growth Potential in the Central Nervous System Biomarkers Market?
North America was the largest region in the central nervous system biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12632

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.